SEC Form 4 · accession 0001144204-15-001832
Akari Therapeutics Plc · AKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark S Cohen
Director
Period of report
Jan 8, 2015
Accepted (ET)
Jan 12, 2015 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001541157
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jan 8, 2015 | X | 50,700 | $0.0167 | A | 50,700 | D | |
| Ordinary SharesF1 | Jan 8, 2015 | X | 152,000 | $0.0153 | A | 152,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Ordinary Shares | $0.0167 | Jan 8, 2015 | X | 50,700 | D | Jan 18, 2005 | Jan 18, 2015 | Ordinary Shares | 50,700 | 0 | I |
| Options to Purchase Ordinary SharesF1 | $0.0153 | Jan 8, 2015 | X | 152,000 | D | Mar 12, 2007 | Mar 12, 2017 | Ordinary Shares | 152,000 | 0 | I |
Explanation of responses
- F1The exercise price for these options to purchase ordinary shares is 0.01 pound sterling.